Post-operative Nausea and Vomiting (PONV) Market is Projected to Expand at a CAG

Posted by Sachin Darakhe on October 4th, 2019

Transparency Market Research (TMR) has published a new report titled, “Post-operative Nausea and Vomiting (PONV) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”, in June 2018. According to the report, the global post-operative nausea and vomiting (PONV) market was valued at US$ 1,608.6 Mn in 2017 and is projected to expand at a CAGR of 8% from 2018 to 2026. Increase in patient population experiencing post-operative nausea and vomiting, rise in adoption rate of combination therapies as well as non-pharmacological treatment modes, surge in funding, and launch of newer therapies are expected to boost the growth of the post-operative nausea and vomiting (PONV) during the forecast period from 2018 to 2026.

North America and Europe are projected to dominate the global PONV market in the near future, primarily due to rise in patient population, steps taken by governments to support the development of novel therapies, and extensive research undertaken for the development of low cost drugs in these regions.The global PONV market in Asia Pacific is anticipated to expand at a high CAGR from 2018 to 2026. This can be ascribed to large patient population, rise in chronic diseases requiring surgical intervention in countries such as China and Japan, and various initiatives undertaken by the government and non-profit organizations to promote awareness about the treatment of post-operative complications. The PONV market in Asia Pacific is expected to expand at a CAGR of 8.5% during the forecast period.

Request a Sample of Post-operative Nausea and Vomiting (PONV) Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2969

• High Incidence Rate and Significant Demand for Combination Therapy to Drive Market

Post-operative nausea & vomiting is one of the most common complications after general anesthesia, occurring in up to 80% patients. Despite impressive advances in the field of anesthesia, 25% to 30% of patients continue to experience PONV. Multiple factors, including the anesthetic agent delivered, are associated with the increased incidence of PONV. A study published by the National Center for Biotechnology Information stated that the incidence of PONV has been reported in 20% to 40% patients with postoperative opioids. However, the incidence rate can increase to nearly 80% in patients with multiple risk factors for PONV, if antiemetic prophylaxis is not appropriate.

• M&A and New Product Development are Key Trends among Leading Players

The report also provides profiles of the leading players operating in the global PONV market. Acacia Pharma, F. Hoffmann-La Roche AG, Novartis AG, Ani Pharmaceuticals, Inc., Camurus AB, Sanofi, Helsinn Holding S.A., Eisai Corporation, Merck & Co., and GlaxoSmithKline Corporation are the prominent players in the market having proprietary products and technologies. The major growth strategy adopted by these companies is new product development.